NAMina Bio Corp is a New York–based biotech company pioneering human-based preclinical research through New Approach Methodologies (NAMs). We integrate patient-derived organoids, organ-on-chip platforms, 3D bioprinted tissues, and AI-driven analytics to replace traditional animal models and accelerate drug discovery.

Serving as an emerging CRO in the Northeast corridor, NAMina Bio provides advanced testing services for oncology, drug screening, therapeutic resistance, and precision medicine applications. Our platform enables high-content, mechanistic studies using models that faithfully mimic the human tumor microenvironment—offering more predictive insights for pharmaceutical and biotech partners.

With strong roots in New York’s biomedical ecosystem, NAMina Bio is actively building collaborations with academic institutions, innovative technology companies, and clinical research centers to drive scientific innovation and support regional economic growth.

Our mission is to transform preclinical development through science-driven, ethical, and human-relevant technologies, reducing reliance on animals while improving translational accuracy and accelerating the path to better therapies.